Skip to main content
OpenTrials
Completed

NCT Number: NCT01672606

Effect of Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea

This study describe the effect of partial neuromuscular blockade of rocuronium on the acute hypoxic ventilatory response in patients with OSA before and after 3 month of CPAP treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

OSA CPAP Hypoxic Ventilatory Response Neuromuscular Blockade Rocuronium

Age range

18 year–70 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Department of Anesthesiology, Surgical Sciences and Intensive Care Medicine, Karolinska University Hospital

Stockholm, se-17176, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male with diagnosed moderate OSA (AHI 15-30), untreated, but planned for CPAP treatment. Healthy except for OSA and well controlled tablet treated hypertension where the treatment has not been changed during the last 3 month. None smokers. 18-70 years old. BMI <35.

Exclusion criteria

  • If they don´t fit the inclusion criteria

Treatment and study plan

Rocuronium

Drug

Partial neuromuscular blockade with rocuronium with a TOF 0.70

Other names: CPAP

Primary outcomes

  1. Hypoxic ventilatory response

    Time frame: At baseline, with CPAP, at TOF 0.70 and at TOF >0.90. At diagnosis and after 3 month of CPAP treatment at home

Secondary outcomes

  1. Hypercarbic ventilatory response

    Time frame: At baseline, with CPAP, at TOF 0.70 and at TOF >0.90. At diagnosis and after 3 month of CPAP treatment at home

  2. Hypoxic ventilatory response

    Time frame: At diagnosis and after 3 month of CPAP treatment at home

  3. Hypoxic ventilatory response during acute CPAP treatment

    Time frame: At diagnosis and after 3 month of CPAP treatment

  4. Hypercarbic ventilatory response

    Time frame: At diagnosis and after 3 month of CPAP treatment at home

  5. Hypercarbic ventilatory response during acute CPAP treatment

    Time frame: At diagnosis and after 3 month CPAP treatment at home

  6. Upper airway obstruction

    Time frame: At TOF 0.70 and TOF >0.90. At diagnosis and after 3 month CPAP treatment.

Sponsors and collaborators

Lead sponsor

Malin Jonsson Fagerlund

Other

Registry information

Official study title

Effect of Partial Neuromuscular Blockade by Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea-before and After Three Month CPAP Treatment. A Non-randomized, Non-blinded Study.

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Aug 27, 2012
Registry last updated
Feb 29, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.